Abstract |
In this study, we sought to evaluate the pharmacokinetics of colistin after intravenous administration of colistimethate sodium (CMS) in the critically ill neonates with Gram-negative bacterial infections. A single intravenous dose of CMS [approximately 150,000 IU/kg, equivalent to 5 mg/kg colistin base activity (CBA)] was administered to 7 critically ill neonates. Mean (±SD) maximum plasma colistin concentration and area under the time-concentration curve from 0 to infinity were 3.0 ± 0.7 µg/mL and 25.3 ± 10.4 µg·h/mL, respectively. Time to maximum concentration, half-life, apparent volume of distribution and clearance were 1.3 ± 0.9 hours, 9.0 ± 6.5 hours, 7.7 ± 9.3 L/kg and 0.6 ± 0.3 L/h/kg, respectively. After a dose regimen of 5 mg/kg CBA every 24 hours, the average concentration expected at steady state is 1.1 ± 0.4 µg/mL. In critically ill neonates, a single intravenous dose of 5 mg CBA/kg (approximately 150,000 IU/kg of CMS) resulted in suboptimal plasma concentrations of colistin. According to our pharmacokinetics data, the dosage of CMS currently used in critically ill neonates is insufficient.
|
Authors | Narongsak Nakwan, Siripa Usaha, Kulkanya Chokephaibulkit, Paola Villani, Mario Regazzi, Roberto Imberti |
Journal | The Pediatric infectious disease journal
(Pediatr Infect Dis J)
Vol. 35
Issue 11
Pg. 1211-1214
(11 2016)
ISSN: 1532-0987 [Electronic] United States |
PMID | 27276179
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- colistinmethanesulfonic acid
- Colistin
|
Topics |
- Administration, Intravenous
- Anti-Bacterial Agents
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Bacteremia
(drug therapy)
- Colistin
(administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
- Critical Illness
- Female
- Humans
- Infant, Newborn
- Infant, Newborn, Diseases
(drug therapy)
- Male
- Pneumonia, Bacterial
(drug therapy)
- Prospective Studies
|